FDA grants accelerated approval to iberdomide with daratumumab for multiple myeloma
The FDA has granted accelerated approval to iberdomide in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy.